Contera Pharma announces acquisition by Korean Bukwang Pharmaceutical

JM-010 to enter global development for L-DOPA induced dyskinesia

03-Dec-2014 - Denmark

Contera Pharma announced that Bukwang Pharmaceutical has acquired 100% of Contera Pharma from its current shareholders. The shareholders received an undisclosed upfront payment and are entitled to future contingent and royalty payments.

Contera Pharma was founded by John Bondo Hansen and Mikael Thomsen to focus on the development of new treatments of movement disorders. The lead program JM-010 is in development for treatment of L-DOPA induced dyskinesia (LID). LID is a debilitating condition that affects Parkinson’s disease patients with no approved treatments. JM-010 has shown very promising effects in pre-clinical models of LID. CEO John Bondo Hansen and CSO Mikael Thomsen will continue in their roles at Contera Pharma in Denmark. 

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances